Latest & greatest articles for rosuvastatin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rosuvastatin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rosuvastatin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rosuvastatin

21. Impact of Rosuvastatin on Contrast-Induced Acute Kidney Injury in Patients at High Risk for Nephropathy Undergoing Elective Angiography (Abstract)

Impact of Rosuvastatin on Contrast-Induced Acute Kidney Injury in Patients at High Risk for Nephropathy Undergoing Elective Angiography Although statins have been shown to prevent contrast-induced acute kidney injury in patients with acute coronary syndromes, the benefit of statins is not known for patients at high risk for nephropathy who undergo elective coronary angiography. Two hundred twenty consecutive statin-naive patients with chronic kidney disease (estimated glomerular filtration rate (...) <60 ml/min/1.73 m(2)) who underwent elective coronary or peripheral angiography were randomly assigned to receive rosuvastatin (40 mg on admission, followed by 20 mg/day; n = 110) or no statin treatment (control group, n = 110). Contrast-induced acute kidney injury was defined by an absolute increase in serum creatinine of ≥0.5 mg/dl or a relative increase of ≥25% measured 48 or 72 hours after the procedure. Contrast-induced acute kidney injury occurred in 15 patients (7.2%), 9 (8.5

2015 EvidenceUpdates Controlled trial quality: uncertain

22. Rosuvastatin for Sepsis-Associated Acute Respiratory Distress Syndrome

Rosuvastatin for Sepsis-Associated Acute Respiratory Distress Syndrome PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2015 PedsCCM Evidence-Based Journal Club

23. A meta-analysis of randomized head-to-head trials for effects of rosuvastatin versus atorvastatin on apolipoprotein profiles. (Abstract)

A meta-analysis of randomized head-to-head trials for effects of rosuvastatin versus atorvastatin on apolipoprotein profiles. To determine which statin will better improve the apolipoprotein (Apo) profiles (ApoA-I levels, ApoB levels, and ApoB/A-I ratios), we performed a meta-analysis of randomized head-to-head trials of rosuvastatin versus atorvastatin therapy. MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched through December 2012 using Web-based search (...) engines (PubMed and OVID). The search terms included "apolipoprotein," "rosuvastatin," "atorvastatin," "randomized," "randomly," and "randomization." Of 42 potentially relevant studies initially screened, 25 reports of randomized trials enrolling 14,283 patients were included. A pooled analysis for the percentage of changes in ApoA-I demonstrated a benefit of rosuvastatin versus atorvastatin in the comparison of all rosuvastatin/atorvastatin dose ratios (mean difference 2.97%, 3.39%, 5.77%, and 6.25

2014 American Journal of Cardiology

24. Rosuvastatin for Sepsis-Associated Acute Respiratory Distress Syndrome. (Full text)

Rosuvastatin for Sepsis-Associated Acute Respiratory Distress Syndrome. In the acute respiratory distress syndrome (ARDS), inflammation in the lungs and other organs can cause life-threatening organ failure. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (statins) can modulate inflammatory responses. Previous observational studies suggested that statins improved clinical outcomes in patients with sepsis. We hypothesized that rosuvastatin therapy would improve clinical outcomes (...) in critically ill patients with sepsis-associated ARDS.We conducted a multicenter trial in which patients with sepsis-associated ARDS were randomly assigned to receive either enteral rosuvastatin or placebo in a double-blind manner. The primary outcome was mortality before hospital discharge home or until study day 60 if the patient was still in a health care facility. Secondary outcomes included the number of ventilator-free days (days that patients were alive and breathing spontaneously) to day 28

2014 NEJM Controlled trial quality: predicted high PubMed abstract

25. [Impact on the carotid intima-medial thickness and safety of rosuvastatin in Chinese patients with carotid atherosclerosis: a meta-analysis]. (Abstract)

[Impact on the carotid intima-medial thickness and safety of rosuvastatin in Chinese patients with carotid atherosclerosis: a meta-analysis]. To evaluate the efficacy and safety of rosuvastatin in Chinese patients with carotid atherosclerosis.A systematic search of Pubmed, EMBase, CENTRAL, CBMdisc, CNKI and WANFANG databases up to January 2013 was performed to identify studies comparing rosuvastatin with a placebo or other statins on carotid intima-medial thickness (IMT) with a minimum follow (...) -up of 6 months in Chinese patients. Meta-analysis was performed by using RevMan 5.0 software after the strict evaluation of the methodological quality of the included studies independently by two reviewers.Twenty-eight studies involving 1 392 individuals were included in this review. The pooled weighted mean difference (WMD) between rosuvastatin and placebo or control on IMT was 0.28 mm (95%CI 0.14-0.42, P < 0.01), with 0.31 mm (95%CI 0.14-0.49, P < 0.01) on 6-8 months and 0.16 mm (95%CI 0.05

2014 Zhonghua xin xue guan bing za zhi

26. Effects of rosuvastatin versus atorvastatin on small dense low-density lipoprotein: a meta-analysis of randomized trials. (Abstract)

Effects of rosuvastatin versus atorvastatin on small dense low-density lipoprotein: a meta-analysis of randomized trials. In addition to their high-intensity effects on the reduction in low-density lipoprotein (LDL) levels, rosuvastatin and atorvastatin would be expected to also reduce small dense LDL (sdLDL) levels. To determine which reduces sdLDL levels more, we performed the first meta-analysis and meta-regression of randomized head-to-head trials of rosuvastatin versus atorvastatin therapy (...) . MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched through April 2012. Eligible studies were prospective, randomized controlled trials of rosuvastatin versus atorvastatin therapy reporting final sdLDL (directly measured or calculated) levels as an outcome. For each study, data regarding final sdLDL levels in both the rosuvastatin and atorvastatin groups were used to generate mean differences (MD) and 95 % confidence intervals (CI). Meta-regression analysis

2014 Heart and vessels

27. Preventive effects of rosuvastatin on atrial fibrillation: A meta-analysis of randomized controlled trials. (Abstract)

Preventive effects of rosuvastatin on atrial fibrillation: A meta-analysis of randomized controlled trials. 23194786 2014 04 22 2015 11 19 1874-1754 167 6 2013 Sep 10 International journal of cardiology Int. J. Cardiol. Preventive effects of rosuvastatin on atrial fibrillation: a meta-analysis of randomized controlled trials. 3058-60 10.1016/j.ijcard.2012.11.084 S0167-5273(12)01567-7 Liu Tong T Korantzopoulos Panagiotis P Li Lijian L Li Guangping G eng Letter Meta-Analysis 2012 11 26 (...) Netherlands Int J Cardiol 8200291 0167-5273 0 Fluorobenzenes 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors 0 Pyrimidines 0 Sulfonamides 83MVU38M7Q Rosuvastatin Calcium IM Atrial Fibrillation epidemiology prevention & control Fluorobenzenes therapeutic use Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use Pyrimidines therapeutic use Randomized Controlled Trials as Topic methods Rosuvastatin Calcium Sulfonamides therapeutic use Atrial fibrillation C-reactive protein Inflammation Meta

2013 International journal of cardiology

28. Effects of atorvastatin and rosuvastatin on renal function: A meta-analysis. (Abstract)

Effects of atorvastatin and rosuvastatin on renal function: A meta-analysis. Atorvastatin (A) and rosuvastatin (R) are highly effective and widely used statins. However, conflicting results have been reported regarding their renal effects. The aim of the present study was to compare the effects of A and R on glomerular filtration rate (GFR) and new onset proteinuria in patients at high cardiovascular risk.Randomized trials about A or R treatments reporting clinical end-points were included

2013 International journal of cardiology

29. Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events (Full text)

Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events Gandhi SK, Jensen MM, Fox KM, Smolen L (...) concluded that rosuvastatin was cost-effective, over a lifetime, compared with generic simvastatin or atorvastatin. The lack of detailed reporting and the highlighted limitations to this study mean that the authors’ conclusions should be considered with caution. Type of economic evaluation Cost-effectiveness analysis, cost-utility analysis Study objective This study evaluated the long-term cost-effectiveness of alternative statin therapies in Swedish patients with a high risk of cardiovascular events

2012 NHS Economic Evaluation Database. PubMed abstract

30. Cost-effectiveness of rosuvastatin 20mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial (Full text)

Cost-effectiveness of rosuvastatin 20mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial Cost-effectiveness of rosuvastatin 20mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial Cost-effectiveness of rosuvastatin 20mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial Ohsfeldt RL, Olsson AG, Jensen MM (...) , Gandhi SK, Paulsson T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study examined cost-effectiveness of rosuvastatin for primary prevention of major cardiovascular disease for various risk levels. The authors concluded that primary

2012 NHS Economic Evaluation Database. PubMed abstract

31. A meta-analysis of randomized head-to-head trials of atorvastatin versus rosuvastatin for reductions in C-reactive protein. (Abstract)

A meta-analysis of randomized head-to-head trials of atorvastatin versus rosuvastatin for reductions in C-reactive protein. 22019059 2012 08 13 2018 12 01 1874-1754 154 1 2012 Jan 12 International journal of cardiology Int. J. Cardiol. A meta-analysis of randomized head-to-head trials of atorvastatin versus rosuvastatin for reductions in C-reactive protein. 78-81 10.1016/j.ijcard.2011.09.065 Takagi Hisato H Umemoto Takuya T eng Comparative Study Letter Meta-Analysis 2011 10 21 Netherlands Int J (...) Cardiol 8200291 0167-5273 0 Fluorobenzenes 0 Heptanoic Acids 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors 0 Pyrimidines 0 Pyrroles 0 Sulfonamides 83MVU38M7Q Rosuvastatin Calcium 9007-41-4 C-Reactive Protein A0JWA85V8F Atorvastatin IM Atorvastatin C-Reactive Protein analysis drug effects Fluorobenzenes therapeutic use Heptanoic Acids therapeutic use Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use Pyrimidines therapeutic use Pyrroles therapeutic use Randomized Controlled Trials

2012 International journal of cardiology

32. Atorvastatin, not rosuvastatin, improves cardiac function in heart failure: a meta-analysis of randomized trials. (Abstract)

Atorvastatin, not rosuvastatin, improves cardiac function in heart failure: a meta-analysis of randomized trials. 22200185 2012 08 10 2018 12 01 1874-1754 155 2 2012 Mar 08 International journal of cardiology Int. J. Cardiol. Atorvastatin, not rosuvastatin, improves cardiac function in heart failure: a meta-analysis of randomized trials. 296-9 10.1016/j.ijcard.2011.11.079 Takagi Hisato H Umemoto Takuya T eng Comparative Study Letter Meta-Analysis 2011 12 24 Netherlands Int J Cardiol 8200291 (...) 0167-5273 0 Fluorobenzenes 0 Heptanoic Acids 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors 0 Pyrimidines 0 Pyrroles 0 Sulfonamides 83MVU38M7Q Rosuvastatin Calcium A0JWA85V8F Atorvastatin IM Atorvastatin Fluorobenzenes therapeutic use Heart Failure drug therapy physiopathology Heptanoic Acids therapeutic use Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use Pyrimidines therapeutic use Pyrroles therapeutic use Randomized Controlled Trials as Topic Rosuvastatin Calcium Stroke

2012 International journal of cardiology

33. Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program. (Abstract)

Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program. Intensive lowering of low-density lipoprotein cholesterol (LDL-C) with statins reduces cardiovascular risk but can cause liver-, muscle-, and possibly renal-related adverse events (AEs). We assessed the effects of rosuvastatin on the risk of developing renal impairment or renal failure among (...) participants in the rosuvastatin clinical development program.The analysis was based on AE data reported by investigators from 36 studies that included 40,600 participants who did not have advanced, pre-existing renal disease. Rates of renal AEs were determined based on time to first occurrence of renal impairment or renal failure.Renal impairment or renal failure was reported in 536 study participants during 72,488 patient-years of follow-up. Renal event rates were higher in patients with history of heart

2012 Atherosclerosis

34. Effects of Rosuvastatin on Progression of Stenosis in Adult Patients With Congenital Aortic Stenosis (PROCAS Trial). (Abstract)

Effects of Rosuvastatin on Progression of Stenosis in Adult Patients With Congenital Aortic Stenosis (PROCAS Trial). Recent trials have failed to show that statin therapy halts the progression of calcific aortic stenosis (AS). We hypothesized that statin therapy in younger patients with congenital AS would be more beneficial, because the valve is less calcified. In the present double-blind, placebo-controlled trial, 63 patients with congenital AS (age 18 to 45 years) were randomly assigned (...) to receive either 10 mg of rosuvastatin daily (n = 30) or matched placebo (n = 33). The primary end point was the progression of peak aortic valve velocity. The secondary end points were temporal changes in the left ventricular mass, ascending aortic diameter, and N-terminal pro-brain natriuretic peptide (NT-proBNP). The median follow-up was 2.4 years (interquartile range 1.9 to 3.0). The mean increase in peak velocity was 0.05 ± 0.21 m/s annually in the rosuvastatin group and 0.09 ± 0.24 m/s annually

2011 EvidenceUpdates Controlled trial quality: predicted high

35. Comparative effectiveness of rosuvastatin versus other statins: a review of clinical effectiveness

Comparative effectiveness of rosuvastatin versus other statins: a review of clinical effectiveness Comparative effectiveness of rosuvastatin versus other statins: a review of clinical effectiveness Comparative effectiveness of rosuvastatin versus other statins: a review of clinical effectiveness Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Comparative effectiveness of rosuvastatin versus other statins: a review of clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2011 Authors' conclusions Evidence suggests that rosuvastatin has the most potent per milligram LDL lowering effect but with appropriate dosage adjustments different statins can provide equivalent LDL reductions. Data suggests

2011 Health Technology Assessment (HTA) Database.

36. The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels (Full text)

The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels Choudhry NK, Patrick AR, Glynn RJ, Avorn J Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of rosuvastatin for apparently healthy men over 50 years old and women over 60 years old, with elevated high-sensitivity C-reactive protein levels (2mg/L or more), but normal low-density lipoprotein cholesterol levels (less than

2011 NHS Economic Evaluation Database. PubMed abstract

37. Rosuvastatin(Crestor)

Rosuvastatin(Crestor) 2011. DAR No 4. Rosuvastatin (Crestor®) - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DAR No 4. Rosuvastatin (Crestor®) DAR No 4. Rosuvastatin (Crestor®) Content tools Share it Another statin! Expensive, potent and doubts on safety Rosuvastatin is the seventh commercialized statin in Spain. Its capacity to lower cholesterol levels is similar to other statins at equivalent doses. No advantage has been shown compared

2011 Drug and Therapeutics Bulletin of Navarre (Spain)

38. Rosuvastatin and the JUPITER trial. A critical appraisal

Rosuvastatin and the JUPITER trial. A critical appraisal Volumen 18. DTB: Vol 18, No 5. November - December 2010 - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DTB: Vol 18, No 5. November - December 2010 DTB: Vol 18, No 5. November - December 2010 Content tools Share it Rosuvastatin and the JUPITER trial. A critical appraisal The role of hs-CRP in the pathogenesis of atherosclerosis still remains unclear. It should not be used

2011 Drug and Therapeutics Bulletin of Navarre (Spain)

39. Rosuvastatin (Crestor®)

Rosuvastatin (Crestor®) Rosuvastatin (Crestor®) Rosuvastatin (Crestor®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Rosuvastatin (Crestor®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG (...) Secretariat Assessment Report Advice No. 1311. 2011 Authors' conclusions Rosuvastatin (Crestor®) is not recommended for use within NHS Wales for the prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors. The clinical and cost effectiveness evidence provided was not sufficient for AWMSG to recommend its use. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH

2011 Health Technology Assessment (HTA) Database.

40. Use of multiple international healthcare databases for the detection of rare drug-associated outcomes: a pharmacoepidemiological programme comparing rosuvastatin with other marketed statins. (Abstract)

Use of multiple international healthcare databases for the detection of rare drug-associated outcomes: a pharmacoepidemiological programme comparing rosuvastatin with other marketed statins. Statins (inhibitors of 3-hydroxy-3-methyl-glutaryl-CoA reductase) are associated with rare but serious adverse events involving the muscle, kidney and liver. To compare the safety profile of rosuvastatin with other marketed statins, four pharmacoepidemiological studies were conducted using different (...) national healthcare databases. These studies used a coordinated methodology to facilitate future meta-analysis.To achieve enhanced estimates of rosuvastatin safety relative to other statins, by performing a meta-analysis of four rosuvastatin safety studies.Outcomes were identified using computerised codes, and validated using hospital records or questionnaires. Incidence estimates were based on current statin exposure. Incidence estimates for hospitalised myopathy, rhabdomyolysis, acute renal failure

2010 Pharmacoepidemiology and drug safety